AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma (NCT03668340)

🧪 Interventions in This Study

• AZD1775 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Dana Farber Cancer Institute — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Uterine Cancer

• Insights Into Participating in Studies for Uterine Cancer — San Francisco, California
• Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer — San Francisco, California
• Investigations of Reproductive Cancers in Women — Birmingham, Alabama
• [18F]FES PET/.CT in Uterine Cancer — Philadelphia, Pennsylvania
• Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking — Durham, North Carolina

Explore by condition: All Uterine Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.